NEW YORK – Medical Home Network this week announced an agreement with Laboratory Corporation of America to integrate lab results into patient records. The deal, MHN said, will enable better care and health at a lower cost for the more than 160,000 Medicaid members served by MHN's accountable care organization. In addition to including real-time lab results in patients' electronic medical records, the MHNConnect data engine will verify that lab analysis of a specimen is complete and alert clinicians to abnormal results. Financial and other terms of the deal were not disclosed.
Luminex said this week that it has received approval from the Committee on Foreign Investment in the US for its previously announced merger with DiaSorin. In a document filed with the US Securities and Exchange Commission, Luminex said it anticipates that the deal will close on or about July 14. In April, DiaSorin announced it had signed an agreement to acquire Luminex for approximately $1.8 billion in cash.
Eurofins Transplant Genomics said this week that its TruGraf proprietary gene expression test for subclinical acute rejection in kidney transplant patients has received coverage from Humana. The payor will offer in-network coverage of the blood test for Medicare Advantage, Medicare HMO, Medicare Network PFFS, Medicare POS, and Medicare PPO patients effective Aug. 1. The test detects subclinical acute rejection in patients with stable kidney function before organ injury and chronic acute rejection begins.
Informatics and digital pathology firm Inspirata announced this week that its UK subsidiary Inspirata Europe received ISO 9001 Quality Management System certification, as well as a UK-backed cybersecurity accreditation. Achieving ISO 9001 means Inspirata’s pathology and oncology artificial intelligence solutions are approved for full inclusion on the Medical IT Departmental Software and Hardware Solutions framework operated by the National Health Service Supply Chain. Inspirata began the process in late 2020 and underwent two audits in spring 2021 to achieve certification.
Aspira Women’s Health announced this week that its OVA1 risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary in AIM Specialty Health’s Clinical Appropriateness Guidelines. AIM Specialty Health is a benefits management company under Anthem Blue Cross Blue Shield. Aspira’s test is included in the guidelines for preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation. OVA1 is also included in the guidelines for the determination of the required surgical approach, operator expertise, and level of care for an adnexal mass.
Thermo Fisher said this week that its board has authorized a quarterly cash dividend of $.26 per common share, payable on Oct. 15 to shareholders of record as of Sept. 15.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.